Trial reportClinical nutrition (Edinburgh, Scotland)2025
Associations of plasma inosine with lipid parameters in a biracial community cohort.
Trial report in Clinical nutrition (Edinburgh, Scotland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00107744 (Clinical Trial of Protein and Blood Pressure), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Trial of Protein and Blood Pressure
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundInosine has been investigated as a dietary supplement for athlete performance, inflammation, and neurological disease. A recent study in a hypercholesterolemic rat model has shown its potential for treating atherosclerosis.
objectiveThis study aimed to investigate the associations between plasma inosine and lipid parameters, and to discover potential mediating pathways.
methodsWe profiled inosine and 886 known metabolites in plasma samples from 1,121 participants of a biracial cohort. Linear regression models assessed inosine's association with total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), log transformed triglycerides (log-TG), and TC to HDL-C ratio (TC/HDL-C), adjusting for relevant covariates. Significant findings were replicated in 78 adults from the Protein and Blood Pressure (ProBP) study, a cross-over randomized control trial by testing longitudinal associations between inosine changes and lipid changes after dietary supplementation of soy protein, milk protein, and carbohydrates. For a replicated association, we employed two complementary approaches to identify potential mediators for enrichment analysis.
resultsIn the discovery cohort, inosine was positively associated with HDL-C (β = 1.77, 95 % confidence interval [CI]: 0.003 to 3.54) and negatively associated with TC/HDL-C (β = -0.24, 95 % CI: -0.41 to -0.08) and log-TG (β = -0.08, 95 % CI: -0.15 to -0.02). These results were replicated in ProBP after soy protein intervention with inosine changes leading to increase of HDL-C (β = 1.82, 95 % CI: 0.36 to 3.27) and decrease of TC/HDL-C (β = -0.14, 95 % CI:-0.28 to -0.002) and TG (β = -12.79, 95 % CI: -21.00 to -4.58). Sex-stratified analyses revealed a more pronounced association in women than men, particularly for HDL-C. Six metabolites and 29 enriched pathways of high confidence were identified.
conclusionIn humans, inosine is associated with better profiles of HDL-C, TC/HDL-C, and log-TG, with more pronounced effects in women for HDL-C. The ProBP trial was registered at ClinicalTrials.gov as NCT00107744.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.